Could Progenics Pharmaceuticals, Inc. (PGNX) See a Reversal After Having Formed Several Months Double Bottom

January 21, 2018 - By Adrian Erickson

Investors sentiment decreased to 1.11 in 2017 Q3. Its down 0.18, from 1.29 in 2017Q2. It worsened, as 22 investors sold Progenics Pharmaceuticals, Inc. shares while 34 reduced holdings. 16 funds opened positions while 46 raised stakes. 58.90 million shares or 4.84% less from 61.90 million shares in 2017Q2 were reported.
Fmr Ltd Liability Corporation reported 0% in Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX). Ls Investment Lc reported 22,806 shares. Fisher Asset Management Llc holds 251,930 shares. Zurcher Kantonalbank (Zurich Cantonalbank) accumulated 2,276 shares. Parkside Bankshares And Trust reported 42 shares or 0% of all its holdings. Lpl Limited Liability has invested 0% of its portfolio in Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX). Voya Invest Management Ltd Llc holds 35,657 shares. Baker Bros Advisors L P owns 3.15 million shares. Credit Suisse Ag holds 0% or 95,088 shares in its portfolio. Duncker Streett & Company holds 0.03% or 14,718 shares in its portfolio. Ardsley Advisory reported 1.87% of its portfolio in Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX). Comerica Bancorporation has 0% invested in Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) for 74,071 shares. Numeric Ltd Liability has 293,400 shares for 0.02% of their portfolio. California Employees Retirement Systems reported 0% of its portfolio in Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX). Creative Planning invested 0% in Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX).

The chart of Progenics Pharmaceuticals, Inc. (PGNX) shows a double bottom with $5.83 target or 7.00 % below today’s $6.27 share price. The 9 months chart pattern indicates high risk for the $440.59 million company. It was reported on Jan, 21 by Finviz.com. If the $5.83 price target is reached, the company will be worth $30.84M less. Double bottoms are rare but powerful chart patterns.

The stock increased 2.79% or $0.17 during the last trading session, reaching $6.27. About 1.30 million shares traded or 21.40% up from the average. Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) has risen 48.41% since January 21, 2017 and is uptrending. It has outperformed by 31.71% the S&P500.

Analysts await Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) to report earnings on March, 8. They expect $-0.21 EPS, down 110.00 % or $0.11 from last year’s $-0.1 per share. After $-0.22 actual EPS reported by Progenics Pharmaceuticals, Inc. for the previous quarter, Wall Street now forecasts -4.55 % EPS growth.

Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) Ratings Coverage

Among 5 analysts covering Progenics Pharm (NASDAQ:PGNX), 5 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Progenics Pharm has $15 highest and $9 lowest target. $13.75’s average target is 119.30% above currents $6.27 stock price. Progenics Pharm had 11 analyst reports since August 6, 2015 according to SRatingsIntel. The stock of Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) has “Buy” rating given on Thursday, October 27 by Aegis Capital. The stock has “Strong Buy” rating by Needham on Monday, February 6. The rating was maintained by Needham on Tuesday, June 20 with “Buy”. Cantor Fitzgerald maintained Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) on Wednesday, August 9 with “Buy” rating. The firm earned “Buy” rating on Friday, August 7 by Zacks. The stock of Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) earned “Buy” rating by Needham on Friday, August 7. The rating was maintained by Jefferies on Tuesday, September 26 with “Buy”. Brean Capital maintained the stock with “Buy” rating in Thursday, August 6 report. The firm has “Buy” rating given on Friday, October 23 by Jefferies. The firm has “Buy” rating by Jefferies given on Thursday, June 8.

More notable recent Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) news were published by: Fool.com which released: “Why Progenics Pharmaceuticals, Inc.’s Shareholders Came to Their Senses” on December 29, 2017, also Seekingalpha.com with their article: “Progenics Pharmaceuticals: An Underappreciated Company You Can’t Afford To Ignore” published on January 18, 2018, Seekingalpha.com published: “Your Daily Pharma Scoop: Progenics Azerda Update, Atara Gets FDA Clearance For …” on December 31, 2017. More interesting news about Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) were released by: Streetinsider.com and their article: “Form SC 13G/A PROGENICS PHARMACEUTICAL Filed by: BlackRock Inc.” published on January 19, 2018 as well as Seekingalpha.com‘s news article titled: “Progenics: The Successful Trial That (Some Claim) Has Failed” with publication date: December 24, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.